daily oral glp-1 receptor agonist orforglipron for adults with obesity Orforglipron, an small-molecule agonist, the treatment of in people type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial Orforglipron, an Oral Small-Molecule GLP-1

Why Hepatic Impairment Matters for Peptide Therapy Liver dysfunction alters drug pharmacokinetics through reduced metabolic capacity, decreased albumin production, portal-systemic shunting, and impaired biliary excretion

It also supports nervous system health which helps reduce weakness, lethargy and neurological stress symptoms

Some remain investigational

It not only enhances insulin production and release, but also decreases glucagon secretion, increases glucose uptake and glycogen synthesis in peripheral tissues, delays gastric emptying, and increases satiety

Which medicines are covered The PAP only covers a specific list of Novo Nordisk registered trademark medicines, which currently includes certain GLP-1 medications (Ozempic, Rybelsus and Xultophy), insulin products (Fiasp, Novolin R, Novolin N and Novolin 70/30, NovoLog Vial, NovoLog PenFill and Flexpen, NovoLog Mix, Tresiba), devices (Novopen, NovoFine), and other selected specialty therapies

doi:10.1073/pnas.2014879117